» Articles » PMID: 22820395

Distribution of Th17 Cells and Foxp3-expressing T Cells in Tumor-infiltrating Lymphocytes in Patients with Uterine Cervical Cancer

Overview
Journal Clin Chim Acta
Specialty Biochemistry
Date 2012 Jul 24
PMID 22820395
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent studies suggest a potential impact of Th17 cells on tumor. In the present study, we investigated the distribution of Th17 cells in relation to Foxp3-expressing T cells in the tumor-infiltrating lymphocytes (TILs) from patients with uterine cervical cancer (UCC), cervical tissues from patients with cervical intraepithelial neoplasia (CIN) and healthy cervical tissues.

Methods: Th17 cells and Foxp3-expressing T cells were evaluated by immunohistochemical staining. IL-6, TGF-β, IL-17 and IL-10 were detected by enzyme-linked immunosorbent assay (ELISA). Immunohistochemical staining for microvessel density (MVD) was performed in order to assess the association of IL-17 expression with angiogenesis.

Results: Compared with controls, patients with UCC or CIN had a higher proportion of Th17 cells and Foxp3-expressing T cells, when the ratio of Th17/Foxp3-expressing T cells in TILs was decreased in individual cases, it was more markedly decreased in TILs than normal cervical tissues. Meanwhile, the cytokine(IL-6, TGF-β and IL-10) concentrations were significantly higher in UCC patients than those in healthy controls. Interestingly, the levels of intratumoral Th17 cells were positively correlated with MVD in tumors.

Conclusions: The imbalance of Th17/Foxp3-expressing T cells may play critical roles in the development and progression of UCC and Th17 cells may promote tumor progression by fostering angiogenesis.

Citing Articles

The prognostic value of Th17/Treg cell in cervical cancer: a systematic review and meta-analysis.

Zhang J, Zhan J, Guan Z, Lin X, Li T, Li M Front Oncol. 2024; 14:1442103.

PMID: 39324000 PMC: 11422014. DOI: 10.3389/fonc.2024.1442103.


The immune microenvironment of cancer of the uterine cervix.

Mastrogeorgiou M, Chatzikalil E, Theocharis S, Papoudou-Bai A, Peoch M, Mobarki M Histol Histopathol. 2024; 39(10):1245-1271.

PMID: 38483012 DOI: 10.14670/HH-18-727.


Tumor immunity: A brief overview of tumor‑infiltrating immune cells and research advances into tumor‑infiltrating lymphocytes in gynecological malignancies (Review).

Wang Z, Deng Z, Dai F, Yuan M, Liu S, Li B Exp Ther Med. 2024; 27(4):166.

PMID: 38476909 PMC: 10928974. DOI: 10.3892/etm.2024.12453.


Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications.

Li Y, Gao X, Huang Y, Zhu X, Chen Y, Xue L Front Oncol. 2023; 13:1114042.

PMID: 37234990 PMC: 10206119. DOI: 10.3389/fonc.2023.1114042.


A Comprehensive View of the Cancer-Immunity Cycle (CIC) in HPV-Mediated Cervical Cancer and Prospects for Emerging Therapeutic Opportunities.

Pena Avila J, Carvalho B, Coimbra E Cancers (Basel). 2023; 15(4).

PMID: 36831674 PMC: 9954575. DOI: 10.3390/cancers15041333.